Data from RTOG 9802 further suggested that PCV is beneficial for IDH-mutant high-risk low-grade glioma and improves both PFS (non-codeleted: HR 0.32, p-value=0.003; codeleted: HR 0.13, p-value<0.001) and OS (non-codeleted: HR 0.38, p-value=0.013; codeleted: HR 0.21, p-value=0.029) (158). Here, IDH1 is linked to central nervous system cancer.